Effect of hepatic cirrhosis on the pharmacokinetics of theophylline in rats

Archives of Pharmacal Research

Volumn 20, Issue 4, 1997, Pages 318-323

  Nam, Bang Hyun ^a   Sohn, Dong Hwan ^a   Ko, Geonil ^a   Kim, Jae Baek ^a  

^a Wonkwang University   (South Korea)

Author keywords

Disease state pharmacokinetics; Experimental hepatic cirrhosis; Protein binding; Theophylline pharmacokinetics

Indexed keywords

EID: 0347847111     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02976193     Document Type: Article

References (21)

1. Ala-Kokko, L., Stenback, F., and Ryhanen, L., Preventive effect of malotilate on dimethylnitrosamine-induced liver fibrosis in the rat. J. Lab. Clin. Med. 113, 177-183 (1989).
2. 4-induced fibrosis of the liver in rats. J. Hepatol. 13(suppl. 3), S26-S34 (1991).
3. Boker, K., Schwarting, G., Kaule, G., Gunzler, V., and Schmidt, E., Fibrosis of the liver in rats induced by bile duct ligation: Effcts of inhibition of prolyl 4-hydroxylase. J. Hepatol. 13(suppl. 3). S35-S40 (1991).
4. National Statistical Office, Korea, Annual report on the cause of death statistics. (1991, 1992, 1993, 1994).
5. Gomita, Y., Furuno, K., Eto, K., Okazaki, M., Suemaru, K., and Araki, Y., Effect of cigarette smoking on theophylline pharmacokinetics in rats. J. Pharm. Pharmacol. 43, 621-624 (1991).
6. Han, S. S., Kim, K. Y., Ham, S. H., Sohn, D. H., and Kim, J. B. Pharmacokinetics of theophylline: Effects of hepatic fibrosis in rats induced by bile duct ligation. Biol. Pharm. Bull. 18, 470-473 (1995).
7. Hendeles, L., Weinberger, M., and Bighley, L., Absolute bioavailability of oral theophylline. Am. J. Hosp. Pharm. 34, 525-527 (1977).
8. Jamall, I. S., Finelli, V. N., and Que Hee, S. S., A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal. Biochem. 112, 70-75 (1981).
9. Jezequel, A. M., Mancini, R., Rinaldesi, M. L., Macarri, G., Venturini, C., and Orlandi, F., A morphological study of the early stages of hepatic fibrosis induced by low doses of dimethylnitrosamine in the rat. J. Hepatol. 5, 174-181 (1987).
10. Kountouras, J., Billing, B. H., and Scheuer, P. J., Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat, Br. J. Exp. Path. 65, 305-311 (1984).
11. Lesko, L. J., Tabor, K. J., and Johnson, B. F., Theophylline serum protein binding in obstructive airways disease. Clin. Pharmacol. Ther. 29, 776-781 (1981).
12. Mangione, A., Imhoff, T .E., Lee, R. V., Shum, L. Y., and Jusko, W. J., Pharmacokinetics of theophylline in hepatic disease. Chest 73, 616-622 (1978).
13. Orcutt, J. J., Kozak, P. P., Gillman, S. A. and Cummins, L. H., Microscale method for theophylline in body fluids by reversed-phase high pressure liquid chromatography. Clin. Chem. 23, 599-601 (1977).
14. Piafsky, K. M., Sitar, D. S., Rangno, R. E., and Ogilvie, R. I., Theophylline disposition in patients with hepatic cirrhosis. N. Engl. J. Med. 296, 1495-1497 (1977).
15. Shand, D. G., Drug disposition in liver disease. N. Engl. J. Med. 296, 1527-1528 (1977).
16. Shargel, L., and Yu, A.B.C., Applied Biopharmaceutics and Pharmacokinetics. 3rd Ed. Prentice-Hall Intl. Inc., New Jersey, pp.595, 1993
17. 4 an adequate model of human cirrhosis? Hepatology 3, 112-120 (1983).
18. Tsukamoto, H., Matsuoka, M., and French, S. W., Experimental model of hepatic fibrosis:a review, Sem. Liv. Dis. 10, 56-65 (1990).
19. Wilkinson, G. R., and Branch, R. A., Effects of hepatic disease on clinical pharmacokinetics. In Benet L. Z., Massoud, N., and Gambertoglio, J. G. (Eds.). Pharmacokinetic Basis for Drug Treatment. Raven Press, New York, pp.49-61, 1984.
20. Williams, R. L., Drug administration in hepatic disease. N. Engl. J. Med. 309, 1616-1622 (1983).
21. φie, S., and Tozer, T. N., Effect of altered plasma protein binding on apparent volume of distribution. J. Pharm. Sci. 68, 1203-1205 (1979).